1.World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. [Online] Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
2.CDC [Online].Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.
3.Smith T, Bushek J, Prosser T. COVID-19 Drug Therapy-Potential Options. Elsevier 2020.[Online] Available from URL: https://www.elsevier.com /__data/assets/pdf_file/0007/988648/COVID-19-Drug-Therapy_Mar-2020.pdf
4.Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020:105938. doi: 10.1016/j. ijantimicag. 2020.105938. [Epub ahead of print]
5. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005 Dec 1;2(1):69.
6. Kashour Z, Riaz M, Garbati MA, et al. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. J Antimicrob Chemother. 2021;76(1):30-42. doi:10. 1093/ jac/dkaa403
7. Elevarasi A et al. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a systematic Review and Meta-analysis. J Gen Intern Med 35(11):3308–14. DOI: 10.1007/s11606-020-06146-w
8. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for COVID-19-Interim WHO Solidarity Trial Results. Available from URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2023184. DOI: 10.1056 /NEJMoa2023184.
9. The RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patient with COVID-19. N Engl J Med 2020; 383:2030-2040
DOI: 10.1056/NEJMoa2022926
10. Pedoman tatalaksana COVID-19. Edisi 3. Available from URL: https://www.papdi.or.id/pdfs/983/Buku%20Pedoman%20Tatalaksana%20COVID-19%205OP%20Edisi%203%202020.pdf.
11. Yao TT , Qian JD , Zhu WY , Wang Y , Wang GQ . A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. [published online February 27, 2020]. J Med Virol. 2020. doi:10.1002/jmv.25729
12. Liu X, Wang Xj. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics. 2020;47(2):119-121. doi: 10.1016/j.jgg.2020.02.001. Epub 2020 Feb 13.
13. Cao B , Wang Y , Wen D , et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. Published online March 18, 2020. doi:10.1056/NEJMoa2001282
14. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020; 396: 1345–52. https://doi.org/10.1016/ S0140-6736(20)32013-4
15. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. Available from URL: https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-
lopinavir-ritonavir-treatment-arms-for-covid-19.
16. Al-Tawfiq JA , Al-Homoud AH , Memish ZA . Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. Published online March 5, 2020. doi:10.1016/j.tmaid.2020.101615
17. Sheahan TP , Sims AC , Leist SR , et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi:10.1038/s41467-019-13940-6
18. Piscoya A, Ng-Sueng LF, Parra del Riego A, Cerna-Viacava R, Pasupuleti V, Roman YM, et al. (2020) Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PLoS ONE 15(12): e0243705. doi:10.1371/journal.pone.0243705
19. Yokoyama Y, Briasoulis A, Takagi H, Kuno T. Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials. Virus Res. 2020;288:198137. doi:10.1016/j.virusres.2020.198137
20. Al-Abdouh A et al. Remdesivir for the treatment of COVID-19: A Systematic review and meta-analysis of randomized controlled trials. Contemporary Clinical Trials (2019), https://doi.org/10.1016/ j.cct.2021.106272
21. WHO. WHO recommends against the use of remdesivir in COVID-19 patients. Available from URL: https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients
22. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at URL: https://www.covid19treatmentguidelines.nih.gov
23. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 10.1016/j.eng.2020.03.007.
24. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020:2020.03.17.20037432
25. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India.2020;76(4):370-6. doi: 10.1016/j.mjafi.2020.08.004
26. Wei F, Moradkhani A, Hemmati Hezaveh H, Mirabootalebi S, Salehi L. Evaluating the Treatment with Favipiravir in Patients Infected by COVID-19: A Systematic Review and Meta-analysis. International Journal of Scientific Research in Dental and Medical Sciences, 2020;2(3): 87-91. doi:10.30485/IJSRDMS.2020.241494.1079
27. Shrestha, D.B., Budhathoki, P., Khadka, S. et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J 2020;17(1); 141. https://doi.org/10.1186/s12985-020-01412-z
28. Wang D, Hu B , Hu C , et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. Published online February 7, 2020. doi:10.1001/ jama.2020.1585
29. Sanders JM et al.Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. Published online April 13, 2020. doi:10.1001/jama.2020.6019
30. Kadam RU , Wilson IA . Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A. 2017;114(2):206-214. doi:10.1073/pnas.1617020114
31. Wang Z , Yang B , Li Q , Wen L , Zhang R . Clinical Features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. Published online March 16, 2020. doi:10.1093/cid/ciaa272
32. Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis [published online ahead of print, 2020 Jul 3]. J Med Virol. 2020;10.1002/jmv.26256. doi:10.1002/jmv.26256
33. Rossignol JF . Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016;9(3):227-230. doi:10.1016/j.jiph.2016.04.001
34. Calderon J M et al. Nitazoxanide against COVID-19 in three explorative scenarios. J Infect Dev Ctries.2020:14(9):982-6. Doi: 10.3855/jidc.13247.
35. Hoffmann M , Kleine-Weber H , Schroeder S , et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. Published online March 4, 2020. doi:10.1016/j.cell.2020.02.052
36. Hofmann-Winkler H, Moerer O, Alt-Epping S, et al. Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. Crit Care Explor. 2020;2(11):e0284. Published 2020 Nov 16. doi:10.1097/CCE.0000000000000284
37. Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. Antiviral Res. 2020;177:104760.
38. Arévalo AP, Pagotto R, Pórfido J, et al. Ivermectin reduces coronavirus infection in vivo: a mouse experimental model. bioRxiv. 2020;Preprint. Available at:https://www.biorxiv.org/content/10.1101/2020.11.02.363242v1
39. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122-1133. Available at:https://www.ncbi.nlm.nih.gov/pubmed/12362927.
40. Chaccour C, Hammann F, Ramon-Garcia S, Rabinovich NR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102(6):1156-1157. Available at: https://www.ncbi.nlm.nih.gov /pubmed /32314704.
41. NIH. The COVID-19 treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19. Available from URL: https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/
42. Mehta P , McAuley DF , Brown M , Sanchez E , Tattersall RS , Manson JJ ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229) :1033-1034. doi:10.1016/S0140-6736(20)30628-0
43. Zhou F , Yu T , Du R , et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
44. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. chinaXiv. Preprint posted March 5, 2020. doi:10.12074/202003.00026
45. Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020 Sep;56(3):106103. doi: 10.1016/j.ijantimicag.2020.106103. Epub 2020 Jul 23. PMID: 32712333; PMCID: PMC7377685.
46. Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis [published online ahead of print, 2020 Nov 5]. Clin Microbiol Infect. 2020;S1198-743X(20)30690-X. doi:10.1016/j.cmi.2020.10.036
47. National Health Commission and State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia. Available from URL: https://www.chinalawtranslate.com/wp-content/uploads/2020/03/Who-translation.pdf
48. León López R, Fernández SC, Limia Pérez L, et al. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial. BMJ Open 2020;10: e039951. doi: 10.1136/bmjopen-2020-039951
49. Cavalli G et al. Interleukin-1 blockade with high dose anakinra n patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol.2020;2:e325-31.
50. Huet T et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol.2020;2(7): E393-400.
51. Novartis. Novartis provides an update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS). Available from URL: https://www.novartis.com/news/media-releases/novartis-provides-update-can-covid-trial-hospitalized-patients-covid-19-pneumonia-and-cytokine-release-syndrome-crs
52. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [published correction appears in Lancet. 2020 Jun 20;395(10241):1906].Lancet. 2020;395(10223):e30-e31. doi:10.1016/S0140-6736(20)30304-4
53. ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized aAdults with COVID-19. NEJM 2020. DOI: 10.1056/NEJMoa2031994
54. FDA. Fact sheet for healthcare providers emergency use authorization (EUA) for baricitinib. Available from URL: https://www.fda.gov/media/143823/download
55. Bellingan et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med. 2014 Feb;2(2):98-107. doi: 10.1016/S2213-2600(13)70259-5. Epub 2013 Dec 23.
56. Walz L, Cohen AJ, Rebaza AP, et al. Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis. Preprint. medRxiv. 2020;2020.08.10.20172189. Published 2020 Aug 11. doi:10.1101/2020.08.10.20172189
57. Mair-Jenkins J , Saavedra-Campos M , Baillie JK , et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90. doi:10.1093/infdis/jiu396
58. Meher B R et al. Effectiveness of Convalescent Plasma Therapy in the Treatment of Moderate to Severe COVID-19 Patients: a systematic review and meta-analysis. J Assoc Physicians India.2020;68(12):35-43. PMID: 33247641.
59. Cao W, Liu X , Bai T , et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. Published online March 21, 2020. doi:10.1093/ofid/ofaa102
60. US FDA. Fact Sheet for Health Care Providers-Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized patients. Available from URL: https://www.fda.gov/media/141478/download
61. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615. PMID: 20610825
62. Zarogoulidis P, Papanas N, Kioumis I, et al. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory disease. Eur J Clin Pharmacol 2012;68:479-503. PMID: 22105373

63. Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20. [Epub ahead of print] PMID: 32205204

64. RECOVERY Collaborative Group. Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv 2020.12. 10.202 459 44; doi:https://doi. org/10. 1101/2020.12.10.20245944
65. Deftereos SG et al. The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design. Helenic Journal of Cardiology. 2020. https:// doi.org/10.1016 /j.hjc.2020.03.002
66. Chen, I-Yin & Moriyama, Miyu & Chang, Ming-Fu & Ichinohe, Takeshi. Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome. Front. Microbiol.2019. https://doi.org /10.3389/fmicb.2019.00050
67. Lopes MIF et al. Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. Available from URL: https://www.medrxiv.org/content/10.1101/2020.08.06.20169573v2
68. Marik PE, Khangoora V, Rivera R, Hooper M, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock. Chest. 2017;151(6):1229-1238. doi: 10.1016/j.chest 2016.11.036. Epub 2016 Dec 6.
69. Carr AC. Vitamin C administration in the critically ill: a summary of recent meta-analyses.Crit Care. 2019;23(1):265. doi:10.1186/s13054-019-2538-y
70. Hemila H, Chalker E. Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis. Nutrients. 2019 Mar 27;11(4). pii: E708. doi: 10.3390/ nu11040708.
71. Baladia E Pizzaro AB, Ortiz-Munoz L, Rada G. COVID-19 LOVE Working Group. Vitamin C for COVID-19: a living systematic review. Medwave 2020;20(6):e7978 doi: 10.5867/medwave.2020.06.7978.
72. Meltzer DO, et al. Association of Vitamin D Status and Other Clinical Characteristic with COVID-19 test results. JAMA Netw Open.2020 3(9):e2019722 (ISSN: 2574-3805)